Abstract
Background A 61-year-old woman with a substantial history of smoking presented with gross hematuria. Cystoscopic evaluation revealed a large bladder tumor.
Investigations Cystoscopic evaluation, histological examination, crosssectional imaging.
Diagnosis High-grade muscle-invasive transitional cell carcinoma (clinical stage T2N0M0, later confirmed as pathologic stage T3aN0M0).
Management Transurethral resection of the bladder tumor, clinical trialbased neoadjuvant treatment with paclitaxel, carboplatin and gemcitabine, and radical cystectomy.
References
Stein JP et al. (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 19: 666–675
Michaelson MD et al. (2004) Selective bladder preservation for muscle-invasive transitional cell carcinoma of the urinary bladder. Br J Cancer 90: 578–581
Shipley WU et al. (1998) Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89–03. J Clin Oncol 16: 3576–3583
Skinner DG et al. (1991) The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 145: 459–464
Stockle M et al. (1992) Advanced bladder cancer (stages pT3, PT4a, pN1 and pN2): improved survival after radical cystectomy and 3 cycles of chemotherapy. Results of a controlled prospective trial. J Urol 148: 302–306
Freiha F et al. (1996) A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 155: 495–499
Sylvester R and Sternberg C (2000) The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why. Ann Oncol 11: 851–856
Advanced Bladder Cancer Meta-analysis Collaboration (2005) Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data. Eur Urol 48: 189–201
[No authors listed] (1999) Neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomized controlled trial. International collaboration of trialists. Lancet 354: 533–540
Grossman HB et al. (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349: 859–866
Hall RR et al. (2002) Updated results of a randomized controlled trial of neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy for muscle-invasive bladder cancer [abstract 710]. Proc Am Soc Clin Oncol 21: 178a
Advanced Bladder Cancer Meta-analysis Collaboration. (2003) Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 361: 1927–1934
Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. (2005) Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient date. Eur Urol 48: 202–205
von der Maase H et al. (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23: 4602–4608
von der Maase H et al. (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter phase III study. J Clin Oncol 18: 3068–3077
Malstrom PU et al. (1996) Five-year follow-up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic cystectomy trial I. J Urol 155: 1903–1906
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Gilbert, S., Lee, C. A case of T2 muscle-invasive bladder cancer treated with neoadjuvant chemotherapy. Nat Rev Urol 3, 675–679 (2006). https://doi.org/10.1038/ncpuro0655
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpuro0655
- Springer Nature Limited